+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07796516

Evaluating Telitacicept with Standard Therapy for Difficult-to-Treat Rheumatoid Arthritis in a Randomized Controlled Trial

Led by Peking University People's Hospital · Updated on 2026-09-01

420

Participants Needed

47

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating telitacicept for adults with difficult-to-treat rheumatoid arthritis, a form of the disease not well controlled by standard treatments. This multicenter, open-label randomized trial aims to assess the safety and effectiveness of telitacicept over a 24-week treatment period, followed by a 2-week follow-up. The study involves patients whose disease remains active despite multiple disease-modifying therapies. Participants are randomly assigned to one of two groups one group receives weekly subcutaneous injections of 160 mg telitacicept along with standard therapy, while the other group continues with standard therapy alone. Standard therapy includes disease-modifying antirheumatic drugs, glucocorticoids, and non-steroidal anti-inflammatory drugs. The treatment period lasts for 24 weeks. During the study, participants will be regularly monitored through clinical assessments and laboratory tests to evaluate their response using measures like the ACR20 response rate at week 24. Researchers will also assess other disease activity indices and safety parameters. After the treatment period, participants have a 2-week follow-up to assess ongoing effects and safety. Total participation lasts about 26 weeks.

CONDITIONS

Brief Title

Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis

Research Team

Z

zhanguo LI, PHD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here